Reuters logo
BRIEF-Matinas BioPharma and NIH/NIAID initiate open-label extension to phase 2A study of MAT2203
March 6, 2017 / 1:26 PM / 9 months ago

BRIEF-Matinas BioPharma and NIH/NIAID initiate open-label extension to phase 2A study of MAT2203

March 6 (Reuters) - Matinas BioPharma Holdings Inc -

* Matinas BioPharma and NIH/NIAID initiate open-label extension to phase 2A study of MAT2203 in chronic mucocutaneous candidiasis

* On track to report phase 2A topline data for MAT2203 in 2Q 2017

* Co to commence 6-month safety open-label extension to phase 2A study with national institutes of health (NIH) Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below